RTP Mobile Logo

Regional Meetings 2017

Beyond the Guidelines: Clinical Investigators Provide Perspectives on Biomarker-Guided Decision-Making for Patients with Non-Small Cell Lung Cancer

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of non-small cell lung cancer (NSCLC). Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Please click here to learn more about our Gastrointestinal Cancers series or here to learn more about our Ovarian Cancer series.

Event Details

Schedule of Events:

Thursday, September 21, 2017
6:30 PM
Registration and dinner
7:00 PM โ€“ 8:00 PM
Education program

Faculty:
Julie R Brahmer, MD
Delaware Society of Clinical Oncology
Newark, Delaware



Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Wednesday, September 27, 2017
5:30 PM
Registration and dinner
6:00 PM โ€“ 7:00 PM
Education program

Faculty:
Corey J Langer, MD
Andrews & Patel Associates PC
Harrisburg, Pennsylvania



Dinner buffet will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Agenda

Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of NSCLC and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Existing and Emerging Research Information with Immune Checkpoint Inhibitors MODULE 2: Evolving Clinical Strategies in the Management of EGFR Mutation-Positive NSCLC MODULE 3: Management of ALK- or ROS1-Positive NSCLC MODULE 4: BRAF, RET and Other Potentially Actionable Mutations

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Julie R Brahmer, MD
Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland

Paul A Bunn Jr, MD
Distinguished Professor and James Dudley Chair
in Cancer Research
University of Colorado Cancer Center
Aurora, Colorado

D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Center
Aurora, Colorado

Alexander E Drilon, MD
Clinical Director
Developmental Therapeutics Clinic
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

David E Gerber, MD
Associate Professor
Division of Hematology-Oncology
Associate Director for Clinical Research
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Sarah B Goldberg, MD, MPH
Assistant Professor of Medicine
Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
Smilow Cancer Hospital
New Haven, Connecticut

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson
Cancer Center
Houston, Texas

Leora Horn, MD, MSc
Associate Professor of Medicine
Clinical Director
Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Edward S Kim, MD
Professor and Chair
Department of Solid Tumor Oncology
and Investigational Therapeutics
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, North Carolina

Mark G Kris, MD
William and Joy Ruane Chair in Thoracic Oncology
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Renato G Martins, MD, MPH
Stephen H Petersdorf Endowed Chair
in Cancer Care
Associate Medical Director
Solid Tumor Adult Oncology
Seattle Cancer Care Alliance
Professor
University of Washington
Seattle, Washington

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Palo Alto, California

Paul K Paik, MD
Assistant Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jyoti D Patel, MD
Professor of Medicine
The University of Chicago
Chicago, Illinois

Nathan A Pennell, MD, PhD
Associate Professor
Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Cleveland, Ohio

Suresh S Ramalingam, MD
Professor of Hematology and Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Mark A Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

David R Spigel, MD
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Thomas E Stinchcombe, MD
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Anne S Tsao, MD
Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas
MD Anderson Cancer Center
Department of Thoracic/Head and
Neck Medical Oncology
Houston, Texas

Everett E Vokes, MD
John E Ultmann Professor
Chairman, Department of Medicine
Physician-in-Chief
University of Chicago Medicine and Biological Sciences
Chicago, Illinois

Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California

Project Chair

Neil Love, MD
President
Research To Practice
Miami, Florida
 

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of NSCLC.

Learning Objectives:

  • Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis for patients with metastatic NSCLC, and use this information to implement a comprehensive approach to genomic assessment.
  • Use mutation status, clinical characteristics and tumor histology to appropriately prioritize front-line and subsequent treatment approaches for patients with metastatic NSCLC.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC, and discern how novel EGFR tyrosine kinase inhibitors can be optimally administered to patients with progressive EGFR mutation-positive disease.
  • Communicate the efficacy and safety of approved and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Recall existing and emerging research information demonstrating the efficacy and safety of anti-PD-1/PD-L1 antibodies for patients with squamous and nonsquamous metastatic NSCLC, and use this information to guide treatment planning.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in NSCLC, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Merck.